AB2231

Anti-DDAH1 antibody

Name: Anti-DDAH1 antibody (ab2231) | Abcam
Brand: Abcam Limited
SKU: AB2231
Price: 565 USD
Availability: InStock
Rating: 4 (3 reviews)

(3 Reviews)

(18 Publications)

Goat Polyclonal DDAH1 antibody. Suitable for ICC, Flow Cyt, WB and reacts with Human samples. Cited in 18 publications. Immunogen corresponding to Synthetic Peptide within Human DDAH1 aa 250 to C-terminus.

View Alternative Names

DDAH, DDAH1, DDAH-1, Dimethylarginine dimethylaminohydrolase 1, DDAHI, Dimethylargininase-1

5 Images

Flow Cytometry - Anti-DDAH1 antibody (AB2231)

Flow Cyt

Unknown

Flow Cytometry - Anti-DDAH1 antibody (AB2231)

Flow cytometric analysis of paraformaldehyde fixed HeLa cells (blue line), permeabilized with 0.5% Triton using ab2231 at 10µg/ml followed by Alexa Fluor 488 secondary antibody at 1µg/ml. IgG control : Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.

Unknown

Immunocytochemistry - Anti-DDAH1 antibody (AB2231)

Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton using ab2231 at 10ug/ml followed by Alexa Fluor 488 secondary antibody at 2ug/ml, showing nuclear and cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control : Unimmunized goat IgG followed by Alexa Fluor 488 secondary antibody.

Unknown

Immunocytochemistry - Anti-DDAH1 antibody (AB2231)

Immunofluorescence analysis of paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton using ab2231 at 10ug/ml followed by Alexa Fluor 488 secondary antibody at 2ug/ml, showing nuclear and cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control : Unimmunized goat IgG followed by Alexa Fluor 488 secondary antibody.

Unknown

Western blot - Anti-DDAH1 antibody (AB2231)

All lanes:

Western blot - Anti-DDAH1 antibody (ab2231) at 0.3 µg/mL

Lane 1:

Human cerebellum

Lane 2:

Human kidney

Lane 3:

Human testes

Predicted band size: 31 kDa

false

Unknown

Western blot - Anti-DDAH1 antibody (AB2231)

All lanes:

Western blot - Anti-DDAH1 antibody (ab2231) at 0.3 µg/mL

Lane 1:

HepG2 cell lysate

Lane 2:

LnCaP cell lysate

Predicted band size: 31 kDa

false

Key facts

Host species

Goat

Clonality

Polyclonal

Isotype

IgG

Carrier free

Reacts with

Human

Applications

Flow Cyt, ICC, WB

applications

Immunogen

Synthetic Peptide within Human DDAH1 aa 250 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.

O94760

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICC" : {"fullname" : "Immunocytochemistry", "shortname":"ICC"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICC-species-checked": "testedAndGuaranteed", "ICC-species-dilution-info": "10 µg/mL", "ICC-species-notes": "", "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "10 µg/mL", "FlowCyt-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "0.1-0.3 µg/mL", "WB-species-notes": "1 hour primary incubation is recommended for this product." }, "Cow": { "ICC-species-checked": "predicted", "ICC-species-dilution-info": "", "ICC-species-notes": "", "FlowCyt-species-checked": "predicted", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" } } }

style

left-column

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Immunogen

Purification notes

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Storage buffer

pH: 7.3 Preservative: 0.02% Sodium azide Constituents: Tris buffered saline, 0.5% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The DDAH1 protein also known as dimethylarginine dimethylaminohydrolase 1 plays an important role in regulating nitric oxide (NO) production by metabolizing asymmetric dimethylarginine (ADMA) an inhibitor of nitric oxide synthase. This enzyme has a molecular mass of approximately 31 kDa and is widely expressed in various tissues including liver kidney and brain. It impacts the cardiovascular system by controlling ADMA levels which influence endothelial function and vascular tone.

Biological function summary

The actions of DDAH1 contribute significantly to cardiovascular homeostasis. Increased levels of ADMA resulting from impaired DDAH1 activity can lead to decreased NO production impacting cardiovascular health. DDAH1 does not form part of a complex but acts individually to affect NO synthesis through ADMA degradation. Understanding the biological roles of DDAH1 helps to appreciate how NO-mediated processes are tightly regulated within the body and its impact on vascular health.

Pathways

DDAH1 participates actively in the nitric oxide synthesis pathway. It modulates the levels of endothelial nitric oxide synthase (eNOS) by regulating ADMA which serves as an eNOS inhibitor. Through this pathway DDAH1 ensures a balance between NO production and regulation supporting vascular homeostasis and blood pressure control. DDAH1 shares functional connections with proteins like eNOS which are central to maintaining vascular health and preventing endothelial dysfunction.

Dysfunction of DDAH1 links closely to cardiovascular diseases and conditions like atherosclerosis. Elevated ADMA levels resulting from compromised DDAH1 activity contribute to endothelial dysfunction a precursor to atherosclerosis. The interconnected role with eNOS highlights DDAH1's importance in managing ADMA concentrations as imbalances can exacerbate disease progression. Investigating the influence of DDAH1 on these diseases offers insights into potential therapeutic targets for cardiovascular pathologies.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Hydrolyzes N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation.

See full target information DDAH1

style

left-column

Publications (18)

Recent publications for all applications. Explore the full list and refine your search

Oxidative medicine and cellular longevity 2022:8151917 PubMed35355865

2022

Cysteine-Rich Whey Protein Isolate (CR-WPI) Ameliorates Erectile Dysfunction by Diminishing Oxidative Stress via DDAH/ADMA/NOS Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Kefan Li,Aiyun Zhu,Jimmy Gutman,Qiang Fu,Shuai Liu

Kidney medicine 3:984-991.e1 PubMed34939007

2021

α-Klotho, Plasma Asymmetric Dimethylarginine, and Kidney Disease Progression.

Applications

Unspecified application

Species

Unspecified reactive species

Jing Qian,Jianyong Zhong,Shaojun Liu,Minhua Yan,Ping Cheng,Chuanming Hao,Yong Gu,Lingyun Lai

Cellular and molecular neurobiology 42:2273-2288 PubMed34014421

2021

Divergent Dimethylarginine Dimethylaminohydrolase Isoenzyme Expression in the Central Nervous System.

Applications

Unspecified application

Species

Unspecified reactive species

Alena A Kozlova,Vinitha N Ragavan,Natalia Jarzebska,Iana V Lukianova,Anastasia E Bikmurzina,Elena Rubets,Toshiko Suzuki-Yamamoto,Masumi Kimoto,Arduino A Mangoni,Raul R Gainetdinov,Norbert Weiss,Michael Bauer,Alexander G Markov,Roman N Rodionov,Nadine Bernhardt

Cancer management and research 13:1-11 PubMed33442289

2021

Circ_0004771 Accelerates Cell Carcinogenic Phenotypes via Suppressing miR-1253-Mediated DDAH1 Inhibition in Breast Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Xubei Ding,Junjun Zheng,Mingxiang Cao

International journal of molecular medicine 43:749-760 PubMed30569164

2018

DDAH2 alleviates myocardial fibrosis in diabetic cardiomyopathy through activation of the DDAH/ADMA/NOS/NO pathway in rats.

Applications

Unspecified application

Species

Unspecified reactive species

Zhen-Dong Zhu,Ji-Ming Ye,Xue-Mei Fu,Xue-Chang Wang,Ji-Yun Ye,Xin-Ran Wu,Peng Hua,Yu-Qiong Liao,Wei Xuan,Jin-Lan Duan,Wei-Yuan Li,Hui Fu,Zhong-Hua Xia,Xuan Zhang

Arteriosclerosis, thrombosis, and vascular biology 38:2345-2357 PubMed29976767

2018

MicroRNA-199a-3p and MicroRNA-199a-5p Take Part to a Redundant Network of Regulation of the NOS (NO Synthase)/NO Pathway in the Endothelium.

Applications

Unspecified application

Species

Unspecified reactive species

Virginie Joris,Elvira Leon Gomez,Lisa Menchi,Irina Lobysheva,Vittoria Di Mauro,Hrag Esfahani,Gianluigi Condorelli,Jean-Luc Balligand,Daniele Catalucci,Chantal Dessy

Scientific reports 7:17900 PubMed29263339

2017

Post-Transcriptional Regulation of Hepatic DDAH1 with TNF Blockade Leads to Improved eNOS Function and Reduced Portal Pressure In Cirrhotic Rats.

Applications

Species

Rat

V Balasubramanian,G Mehta,H Jones,V Sharma,N A Davies,R Jalan,R P Mookerjee

Scientific reports 7:13996 PubMed29070803

2017

MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1.

Applications

Unspecified application

Species

Unspecified reactive species

Julie-Ann Hulin,Sara Tommasi,David Elliot,Dong Gui Hu,Benjamin C Lewis,Arduino A Mangoni

Pain 156:2052-2060 PubMed26098438

2015

Dimethylarginine dimethylaminohydrolase 1 is involved in spinal nociceptive plasticity.

Applications

WB, IHC-FoFr

Species

Rat, Rat

Richard D'Mello,Claire A Sand,Sophie Pezet,James M Leiper,Egle Gaurilcikaite,Stephen B McMahon,Anthony H Dickenson,Manasi Nandi

Journal of hepatology 62:325-31 PubMed25152204

2014

Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.

Applications

WB, IHC

Species

Human, Human

Rajeshwar P Mookerjee,Gautam Mehta,Vairappan Balasubramaniyan,Fatma El Zahraa Mohamed,Nathan Davies,Vikram Sharma,Yasuko Iwakiri,Rajiv Jalan

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-DDAH1 antibody

Flow Cytometry - Anti-DDAH1 antibody (AB2231)

Immunocytochemistry - Anti-DDAH1 antibody (AB2231)

Immunocytochemistry - Anti-DDAH1 antibody (AB2231)

Western blot - Anti-DDAH1 antibody (AB2231)

Western blot - Anti-DDAH1 antibody (AB2231)

Key facts

Host species

Clonality

Isotype

Carrier free

Reacts with

Applications

Immunogen

Reactivity data

Properties and storage information

Form

Purification technique

Purification notes

Storage buffer

Shipped at conditions

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (18)

Alternative Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Complementary Products

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Product promise